Stem Cell Therapy for Pulmonary Fibrosis

Pulmonary Fibrosis (PF) is the disease of the lungs due to damage of lung tissue and cells. Medications, oxygen therapies, and transplantations are treatments with a great variety of side effects. To minimize the side effects and complications, Stem Cell Therapy is the best suitable treatment option for PF.

Pulmonary fibrosis is a lung disease characterized by the scarring and thickening of lung tissue, which impairs the lungs' ability to function properly. As the tissue becomes thicker, it becomes increasingly difficult for the lungs to efficiently transfer oxygen into the bloodstream, leading to symptoms such as shortness of breath.

The scarring in pulmonary fibrosis can be caused by various factors, including environmental exposure, infections, and autoimmune diseases. When the cause of the scarring is unknown, the condition is referred to as idiopathic pulmonary fibrosis.

Pulmonary Fibrosis refers to a condition in which the lung tissue becomes scarred, leading to breathing difficulties. It can be caused by various factors, such as environmental exposures, infections, or autoimmune diseases. When the underlying cause is identified, treatment can be tailored to address the specific condition.

In contrast, Idiopathic Pulmonary Fibrosis (IPF) occurs when the cause of the fibrosis remains unknown. Despite extensive testing, the exact origin of the lung scarring cannot be determined, making IPF a distinct form of pulmonary fibrosis that requires a different treatment approach.

Pulmonary fibrosis (PF) can develop due to a variety of factors. The most common causes include:

Environmental and Occupational Exposures: Prolonged inhalation of substances such as grain dust, asbestos fibers, silica dust, coal dust, and hard metal dust can contribute to lung damage leading to PF.

Radiation Therapy: Exposure to radiation treatments, particularly those targeting the chest, can increase the risk of developing PF.

Medications: Certain drugs, including heart medications, anti-inflammatory drugs, antibiotics, and chemotherapy agents, can be associated with pulmonary fibrosis as a side effect.

Underlying Medical Conditions: PF can also result from autoimmune or inflammatory diseases, such as:

o Sarcoidosis

o Pneumonia

o Scleroderma

o Dermatomyositis

o Mixed connective tissue disease

o Rheumatoid arthritis

o Polymyositis

o Systemic lupus erythematosus (SLE)

Gastroesophageal Reflux Disease (GERD): Chronic acid reflux can damage lung tissue, contributing to the development of pulmonary fibrosis.

The most common risk factors for pulmonary fibrosis include:

Genetic predisposition: A family history of pulmonary fibrosis increases the likelihood of developing the disease.

Smoking: A significant risk factor that contributes to lung damage and fibrosis.

Gender: Men are more likely to be affected by pulmonary fibrosis compared to women.

Age: The disease is more prevalent in middle-aged and older adults.

Occupational exposure: Jobs in industries such as construction, mining, and farming increase the risk due to prolonged exposure to pollutants and environmental toxins.

Cancer treatments: Certain chemotherapy drugs and radiation therapy are known to increase the risk of pulmonary fibrosis.

While the lung scarring caused by pulmonary fibrosis is irreversible, there are treatments aimed at slowing disease progression and managing symptoms. Although no treatment has been definitively proven to halt the progression of PF, the most common interventions include:

Medications:

o Nintedanib and Pirfenidone are commonly prescribed to slow the decline of lung function.

Oxygen Therapy:

o Used to reduce complications from low oxygen levels and improve quality of life.

Pulmonary Rehabilitation:

o A comprehensive program that includes physical exercises, breathing techniques, and nutritional counseling to enhance endurance and lung health.

Lung Transplantation:

o In severe cases, a lung transplant may be considered. However, it carries risks such as complications, infections, and the potential for rejection.

Stem cell therapy utilizes the body's natural repair mechanism to promote healing and regeneration. Stem cells, which are found in fat cells, bone marrow, and donor cord blood, have the unique ability to activate the growth of new, healthy cells in damaged tissues. In this therapy, mesenchymal stem cells (MSCs) from donor cord blood are applied to the affected area, encouraging the body's repair processes.

By enhancing the body's ability to regenerate tissue, stem cell therapy boosts the natural healing mechanisms, facilitating recovery and introducing new, healthy stem cells to the site of damage.

Stem cell therapy is considered one of the most advanced and effective treatment options for Idiopathic Pulmonary Fibrosis (IPF). This condition involves severe damage and destruction of lung tissue, which can potentially be repaired through the use of mesenchymal stem cells (MSCs).

Unlike traditional treatments that primarily manage symptoms, MSCs target the underlying cause of IPF by promoting the regeneration of damaged lung tissue. By focusing on tissue repair and regeneration, stem cell therapy offers a promising approach to addressing the root cause of the disease rather than merely alleviating symptoms.

Generally, Stem Cell Therapy has a satisfactory safety profile, good prognosis, and effectiveness.

The most frequent or common risk factors of SCT can be:

Lethargy and fatigue

Bleeding from the site of injection

Fever

Painful injection area /site

Allergic reactions

The Stem Cell Therapy (SCT) at The Renue Medical Centre is a holistic approach to treating Pulmonary Fibrosis (PF).

Your Renue Journey does not end after your last day of SCT. We follow up with you to assert your progress, since the treatment of Pulmonary Fibrosis with Stem Cells consists of four phases:

Pre-treatment: Clinical evaluation, lab test results, and other diagnostic procedures. You will take our Renue Epigenetic Test powered by TruDiagnostics that will assert your biological age and other important health markers. Your TruDiagnostics test is part of The Renue Difference. It provides your doctor with critical information about your health and your true age (biological vs. chronological).

After the epigenetic test and we have received all your medical records, your Patient Advisor will assist you in planning your travel to Puerto Vallarta.

Treatment day: The treatment starts with taking a specific amount of blood through apheresis. After taking the Stem Cells, the rest of the blood is returned to the donor.

30, 60 & 90 days post-treatment follow-up: PF symptoms clinical evaluation, flare-up frequency, and lab test results

Six months post-treatment: PF symptoms clinical evaluation, flare-up frequency, lab test results, X-ray report, and review of the diagnostic criteria.

SCT to live a better life: Benefits and outcomes

The effectiveness of Stem Cell Treatment can improve all your symptoms, causing a considerable impact on your quality of life and daily activities.

As part of The Renue Difference, you will receive three Hyperbaric Chamber sessions that greatly improve SCT efficacy and stimulate the body cells to combat Pulmonary Fibrosis. These sessions comprise three days: one day before treatment, after treatment, and on the day of treatment.

According to results, clinical outcomes, and pre-and post-treatment observations, SCT has been shown to help:

Reduce Pulmonary Fibrosis progression

Speed up tissue repair

Regrow and repair tissues after six months

After the SCT procedure, an MRI test depicts the further need for the treatment at a specific body site.

Talk to our Patient Advisor to learn more about SCT at The Renue Medical Centre.

Expected results and prognosis:

Improved breathing, more endurance, and improved quality of life.

Fever, lethargy, and pain are managed through the appropriate drugs along with the treatment. Bleeding and swelling of the injured site is manageable via proper technique. Allergic reactions are preventable through pre-injection history and care.

Stem Cell Therapy is a new and promising method of treating Pulmonary Fibrosis. It has the potential to be more effective than previous methods and also carries less risk. At present, stem cell technology is still in the developmental stage, but rapid developments and advances indicate its potential uses in direct treatments of Pulmonary Fibrosis.